Clinical studies and abstracts

We’re committed to giving you all the clinical information about Tresiba^® you need to help your patients. The links below will provide you access to the published clinical data on PubMed.gov, the website of the US National Library of Medicine, National Institutes of Health.

Marso et al 2017 (DEVOTE)

Efficacy and safety of degludec versus glargine in type 2 diabetes

Marso SP, McGuire DK, Zinman B, et al. N Engl J Med. 2017;377(8):723-732.

Zinman et al 2012 (BEGIN: Once Long)

Insulin-naïve adults with type 2 diabetes on Tresiba^®, 52-week study

Zinman B, Philis-Tsimikas A, Cariou B, et al; on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators. Diabetes Care. 2012;35(12):2464-2471.

Heller et al 2012 (BEGIN: Basal-Bolus Type 1)

Adults with type 1 diabetes converting to Tresiba^®, 52-week study

Heller S, Buse J, Fisher M, et al; on behalf of the BEGIN Basal-Bolus Type 1 Trial Investigators. Lancet. 2012;379(9825):1489-1497.

Gough et al 2013 (BEGIN: Low Volume)

Insulin-naïve adults with type 2 diabetes starting on Tresiba^® U-200, 26-week study

Gough SCL, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Diabetes Care.2013;36(9):2536-2542.

Meneghini et al 2013 (BEGIN: FLEX T2)

Adults with type 2 diabetes inadequately controlled on basal insulin alone, oral antidiabetic drugs (OADs) alone, or both basal insulin and OADs, 26-week study

Meneghini L, Atkin SL, Gough SCL, et al; on behalf of the NN1250-3668 (BEGIN FLEX) Trial Investigators. Diabetes Care. 2013;36(4):858-864.

Tresiba^® offers proven
A1C control¹

Selected Important Safety Information

Contraindications

Tresiba^® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba^® or one of its excipients

Warnings and Precautions

Never Share a Tresiba^® FlexTouch^® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba^® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens
Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant anti-diabetic treatment may be needed
Hypoglycemia is the most common adverse reaction of insulin, including Tresiba^®, and may be life-threatening

Indications and Usage

Tresiba^® (insulin degludec injection) is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use

Tresiba^® is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications

Tresiba^® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba^® or one of its excipients

Warnings and Precautions

Never Share a Tresiba^® FlexTouch^® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba^® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens
Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant anti-diabetic treatment may be needed
Hypoglycemia is the most common adverse reaction of insulin, including Tresiba^®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba^®
As with all insulins, Tresiba^® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba^®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

Adverse reactions commonly associated with Tresiba^® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain

Drug Interactions

There are certain drugs that may cause clinically significant drug interactions with Tresiba^®.
- Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
- Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones
- Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine
- Drugs that may blunt the signs and symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine

Please click here for Prescribing Information

Reference:

Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; November 2018.